CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first ...

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies with a market capitalization of $704 million, has been making strides in its oncology pipeline while ...

Shares in vaccine developers jumped on Tuesday after the US reported its first human death from the H5 strain of bird flu.

CureVac (NASDAQ:CVAC – Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 3,940,000 shares ...

Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89% ...